Osteoporosis Flashcards

1
Q

Osteoclast vs osteoblast

A

Osteoclast (resorption of bone)
Osteoblast (rebuilding of bone)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

When does osteoporosis occur?

A

When there is an imbalance in the osteoclast and osteoblast function
- bone formation does not replace resorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is a major contributor to an increased risk of osteoporosis in older female patients?

A

Menopause

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What BMD T-score defines osteoporosis?

A

BMD T-score ≤−2.5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What does this score indicate?

A

2.5 standard deviations below a normal young adult reference

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What conditions are associated with increased risk of fractures if patient is postmenopausal or 50-64 years of age?

A

Postmenopausal or 50-64 years of age with:
- Parent with hip fracture
- Osteopenia on x-ray
- Current smoking
- High alcohol intake
- Low body weight <60kg
- Major weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What conditions are risk factors for fractures regardless of age?

A
  • History of fragility
  • Premature menopause (<45)
  • Hyperthyroidism
  • Cushing syndrome
  • Hyperparathyroidism
  • Renal diseases
  • Organ transplantation
  • GI diseases (gastric surgery, bariatric surgery)
  • Disorders associated with rapid bone loss or fracture (Ex: RA, multiple myeloma)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What medications are associated with increased risk of fractures?

A
  • Androgen deprivation therapy
  • Anticoagulants
  • Antiepileptic drugs
  • Antiretroviral therapy
  • Aromatase inhibitors
  • Chemotherapy
  • Corticosteroids (prolonged)
  • Cyclosporine
  • Loop diuretics
  • PPI
  • SSRII
  • Thiazolidinediones
  • High dose Vitamin A
  • Sedatives/antipsychotics that increase the risk of falls
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What tool is good for identifying fracture risk?

A

Fracture risk assessment tool (FRAX)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What tool is good for identifying bone density?

A

CAROC system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How can therapeutic choices for osteoporosis be divided into?

A

Prevention and treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Which population is prevention therapy particularly important for?

A

Patients on chronic corticosteroid therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are non-pharm choices that we should recommend for everyone?

A

Regular exercise
- weight bearing, strength training

Fall prevention
- minimize physical hazards and drugs

Dietary supplement
- protein, calcium, vitamin D

Avoid excessive alcohol and caffeine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How should the nutritional supplement of calcium be managed?

A

Diet first, and then supplement if necessary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Is calcium supplementation associated with increased risk of CV events?

A

No. Recent data has refuted this claim.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Vitamin D deficiency is a major issue in Canada. Requirements are often not met in diet. How much Vitamin D is recommended by Osteoporosis Canada?

A

800-2000 units of Vitamin D/day for those over the age of 50 and are at risk of osteoporosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Is there any benefit/harm with going above this amount?

A

No benefit.
Seems to have enhanced bone loss when Vit D doses exceed 4000 units per day.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What agents are used to treat osteoporosis?

A

Antiremodelling or antiresorptive agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Why is antiremodelling a more accurate description compared to antiresorptive agents?

A

They do more than suppress osteoclast activity. They also reduce resorption and bone formation.

Corrects remodelling imbalance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Which drug class in the mainstay of osteoporosis treatment?

A

Bisphosphonate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Which drugs are under the bisphosphonate drug class?

A

Alendronate
Risedronate
IV zoledronate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Bonus: What must be corrected prior to initiating therapies like Prolia or Jubbonti?

A

Hypocalcemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the mechanism of action for bisphosphonates?

A
  1. Bind to bone mineral
  2. When osteoclasts being bone-resorption, they secrete acid to dissolve bone mineral
  3. Acidic environment allows bisphosphonate to cross cell membrane and enter osteoclast -> cause apoptosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Of the bisphosphonates, which two agents are considered first-line?

A

Alendronate and risedronate

Etiodronate was the first bisphosphonate to be used but is used less commonly now

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Is there a difference in endpoints between alendronate and risedronate?

A

Alendronate had greater effect on BMD, but fracture prevention showed no difference.

Another study showed that risedronate had greater fracture prevention than alendronate

26
Q

What administration counselling points must be discussed with patients?

A

Take on an empty stomach
Water only

27
Q

What are main side effects with bisphosphonates?

A

Minor GI upset
Allergic reactions

28
Q

When is IV zoledronate used?

A

Can be a first-line agent if:

Patient cannot tolerate GI side effects of oral agent

When oral agents are ineffective

Unable to adhere to admin instructions

Adherence (IV is only once a year)

29
Q

Is there evidence that bisphosphonates interfere with the process of fracture healing?

30
Q

What type of fractures have there been case reports of with the use of bisphosphonates?

A

Atypical femoral fractures

Similar to stress fractures but are spontaneous

31
Q

Patients treated for ≥___ years with bisphosphonate had a chance of developing atypical femoral fractures.

32
Q

In contrast, the incidence of “typical” hip fracture is also high.

However, after ___ years of bisphosphonate therapy, the risk of AFF associated with bisphosphonate therapy appears to far outweigh the number of hip and clinical fractures prevented

33
Q

With this knowledge in mind, how should we manage atypical femur fracture?

A

Encourage patients who are not at high risk of osteoporotic fractures to stop bisphosphonates after 5 years of therapy.

If continuing for >5 years, advise patient to monitor.
- Thigh or groin pain that may be unilateral or bilateral.

34
Q

Following the cessation of bisphosphonate, how long does it take for risk of AFF to decline?

A

Within a year

35
Q

If AFF is identified, how do we manage?

A

Do not restart bisphosphonate.

Consider an anabolic agent like teriparatide to increase bone turnover and hasten repair

Refer patient to osteoporosis specialist. Consider alternative therapy like estrogen, denosumab etc.

36
Q

When are bisphosphonate drug holidays usually recommended?

A

If patient has stable BMD and has been free of fractures during therapy:

After 5 years of oral therapy or
3 annual infusions of IV zoledronate

37
Q

How long are drug holidays usually?

38
Q

What biologic drug class is approved for the treatment of osteoporosis?

A

RANK Ligand Inhibitors

39
Q

What drugs are considered RANK ligand inhibitor?

A

Denosumab
Jubbonti (biosimilar)

40
Q

What is the mechanism of action of RANK ligand inhibitors?

A

Prevents interaction with RANK receptors on the surface of osteoclasts. Regulates RANKL pathways

Suppresses bone resorption and increases BMD

41
Q

Denosumab should be considered as first line. However, ______ is what limits its use compared to bisphosphonate.

42
Q

Practitioners often use denosumab first line in those with _______ cases of osteoporosis. These include?

A

Severe
- history of osteoporotic fracture
- multiple risk factors for fractures
- those who have failed or are intolerant of other therapies

43
Q

Are drug holidays recommended for denosumab? Why?

A

No.

Unlike bisphosphonates, denosumab is not retained in the skeleton. If therapy is stopped for more than 6 months, there is rapid increase in bone remodelling.

Generally well tolerated. Infrequent cases of AFF and ONJ

44
Q

What is a side effect we must monitor for with denosumab?

A

Hypocalcemia
Particularly in patients with Vitamin D deficiency renal insufficiency

45
Q

Are bisphosphonates safe in renal insufficiency?

46
Q

Is denosumab safe in renal insufficiency?

47
Q

What are alternatives to bisphosphonates?

A

Estrogen
Raloxifene
Teriparatide
Denosumab
Calcitonin

48
Q

What drug is under the SERM (selective estrogen receptor modulator) drug class?

A

Raloxifene

49
Q

What is the mechanism of action of raloxifene?

A

Estrogen antagonist in breast and uterine tissue, but has estrogen like activity in bone and lipid metabolism

50
Q

What increased risk does raloxifene come with?

A

Like estrogen, it may increase risk of deep vein thrombosis and pulmonary embolism in postmenopausal women

51
Q

When does raloxifene come into play?

A

In postmenopausal bone loss as second line therapy

52
Q

What is E/PT therapy?

A

Estrogen
Estrogen/progesterone hormone therapy

53
Q

When does E/PT therapy come into play?

A

For those experiencing early menopause (before 45 y).

Should be taken until age of menopause (~51 years of age)

54
Q

E/PT therapy used to be considered first line in post-menopausal women. However, it is no longer recommended.

What population may this still be true in?

A

May still be used first-line in post menopausal women if patient would like a prevention therapy and who also wish to receive treatment for menopausal symptoms (Ex: vasomotor symptoms)

55
Q

If they do choose to use this therapy, what risks should the patient be educated on?

A

Reduction in hip and other fractures must be balanced against the increased risk of breast cancer and heart disease

56
Q

Salmon calcitonin nasal spray used to be recommended as second line therapy. However, why was it discontinued?

A

Increased risks of cancer

57
Q

As an alternative to salmon calcitonin nasal spray, what other formulation is now available?

A

Injectable salmon calcitonin

58
Q

What agents are under the anabolic agents?

A

Teriparatide
Abaloparatide
Romosozumab
Strontium Ranelate

59
Q

Teriparatide therapy is expensive, so its use is limited. However, when may it be considered as first line therapy?

A

Severe osteoporosis
(including corticosteroid induced osteoporosis)

60
Q

After teriparatide resolves the severe bone density loss, what should we follow it with?

A

Subsequent treatment with a bisphosphonate or denosumab is advised